- Leading proxy advisory firms ISS and Glass Lewis both recommend shareholders vote in favor of all proposals for Teva Pharmaceuticals' (TEVA) annual meeting.
- After a thorough analysis of Teva's compensation policy, Glass Lewis stated: "Overall, the Company has provided adequate disclosure regarding its executive compensation program. We have not identified any significant issues for shareholder concern and believe that the company has designed appropriate incentive plans that will link pay for performance going forward."
- Shares +0.5% AH.
at Zacks.com (Nov 5, 2014)